O Shaughnessy Asset Management LLC Grows Holdings in Boston Scientific Co. (NYSE:BSX)

O Shaughnessy Asset Management LLC grew its holdings in Boston Scientific Co. (NYSE:BSX) by 6.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 169,665 shares of the medical equipment provider’s stock after acquiring an additional 11,021 shares during the period. O Shaughnessy Asset Management LLC’s holdings in Boston Scientific were worth $11,620,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in BSX. Louisiana State Employees Retirement System purchased a new stake in Boston Scientific during the 4th quarter valued at approximately $5,116,000. Sierra Summit Advisors LLC bought a new stake in shares of Boston Scientific in the fourth quarter worth about $8,038,000. TD Asset Management Inc lifted its position in shares of Boston Scientific by 10.7% in the fourth quarter. TD Asset Management Inc now owns 1,615,932 shares of the medical equipment provider’s stock worth $93,417,000 after buying an additional 155,565 shares in the last quarter. HealthInvest Partners AB bought a new position in Boston Scientific during the fourth quarter valued at approximately $3,746,000. Finally, BI Asset Management Fondsmaeglerselskab A S increased its stake in Boston Scientific by 225.6% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 105,671 shares of the medical equipment provider’s stock worth $7,237,000 after acquiring an additional 73,219 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $77.30, for a total transaction of $539,785.90. Following the completion of the sale, the executive vice president now owns 42,908 shares in the company, valued at approximately $3,316,788.40. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, Director Edward J. Ludwig sold 9,818 shares of the business’s stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $73.29, for a total transaction of $719,561.22. Following the sale, the director now owns 41,374 shares in the company, valued at $3,032,300.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction that occurred on Monday, July 1st. The shares were sold at an average price of $77.30, for a total transaction of $539,785.90. Following the completion of the transaction, the executive vice president now directly owns 42,908 shares of the company’s stock, valued at $3,316,788.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,259 shares of company stock valued at $5,344,014. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Up 0.4 %

BSX stock traded up $0.32 during trading on Tuesday, reaching $78.59. 6,705,798 shares of the company traded hands, compared to its average volume of 6,186,285. The business has a 50 day simple moving average of $76.32 and a 200 day simple moving average of $69.98. Boston Scientific Co. has a 12 month low of $48.35 and a 12 month high of $79.43. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.14 and a current ratio of 1.66. The company has a market capitalization of $115.30 billion, a price-to-earnings ratio of 65.76, a price-to-earnings-growth ratio of 2.67 and a beta of 0.78.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 24th. The medical equipment provider reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.51 by $0.05. Boston Scientific had a net margin of 12.06% and a return on equity of 16.39%. The business had revenue of $3.86 billion for the quarter, compared to analysts’ expectations of $3.68 billion. On average, equities research analysts anticipate that Boston Scientific Co. will post 2.32 earnings per share for the current fiscal year.

Analyst Ratings Changes

BSX has been the subject of a number of recent research reports. Truist Financial raised their target price on shares of Boston Scientific from $86.00 to $90.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Barclays boosted their price objective on Boston Scientific from $70.00 to $78.00 and gave the stock an “overweight” rating in a research note on Friday, April 26th. Evercore ISI boosted their target price on Boston Scientific from $78.00 to $81.00 and gave the company an “outperform” rating in a research report on Tuesday, July 2nd. Morgan Stanley raised their price target on Boston Scientific from $79.00 to $92.00 and gave the stock an “overweight” rating in a research report on Monday, July 15th. Finally, Raymond James increased their target price on shares of Boston Scientific from $73.00 to $85.00 and gave the company a “strong-buy” rating in a research note on Thursday, April 25th. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Boston Scientific has a consensus rating of “Moderate Buy” and an average target price of $82.29.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.